LSBCF (LakeShore Biopharma Co) Debt-to-EBITDA : -1.83 (As of Mar. 2025)


What is LakeShore Biopharma Co Debt-to-EBITDA?

LakeShore Biopharma Co LSBCF Debt-to-EBITDA is -1.83 as of Mar. 2025.

Debt-to-EBITDA measures a company's ability to pay off its debt.

LakeShore Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $53.92 Mil. LakeShore Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $3.24 Mil. LakeShore Biopharma Co's annualized EBITDA for the quarter that ended in Mar. 2025 was $-31.33 Mil. LakeShore Biopharma Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -1.82.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for LakeShore Biopharma Co's Debt-to-EBITDA or its related term are showing as below:

LSBCF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.16
* Ranked among companies with meaningful Debt-to-EBITDA only.

LakeShore Biopharma Co  (OTCPK:LSBCF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

LakeShore Biopharma Co Debt-to-EBITDA Related Terms

LakeShore Biopharma Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Debt-to-EBITDA Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Debt-to-EBITDA
-0.16 -5.66 -6.49 -1.15 -8.54

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only -2.53 -1.95 -0.94 6.50 -1.83

LSBCF vs ACUT, PPCB, ENSC: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Debt-to-EBITDA falls into.


LakeShore Biopharma Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

LakeShore Biopharma Co's Debt-to-EBITDA for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(53.922 + 3.242) / -6.696
=-8.54

LakeShore Biopharma Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(53.922 + 3.242) / -31.33
=-1.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -1.83 mean?
LakeShore Biopharma Co (LSBCF) has a Debt-to-EBITDA of -1.83 as of Mar. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on LakeShore Biopharma Co.
Is LakeShore Biopharma Co's Debt-to-EBITDA too high?
LakeShore Biopharma Co's current Debt-to-EBITDA is -1.83.
How does LakeShore Biopharma Co's Debt-to-EBITDA compare to ACUT and PPCB?
LakeShore Biopharma Co's Debt-to-EBITDA of -1.83 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on LakeShore Biopharma Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Debt-to-EBITDA is -1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Debt-to-EBITDA of -1.83. The current Debt-to-EBITDA is -1.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Debt-to-EBITDA is -1.83 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.